arGEN-X SE ADR (ARGX): Price and Financial Metrics
GET POWR RATINGS... FREE!
ARGX POWR Grades
- Growth is the dimension where ARGX ranks best; there it ranks ahead of 65.91% of US stocks.
- ARGX's strongest trending metric is Sentiment; it's been moving down over the last 177 days.
- ARGX ranks lowest in Quality; there it ranks in the 0th percentile.
ARGX Stock Summary
- For ARGX, its debt to operating expenses ratio is greater than that reported by only 5.41% of US equities we're observing.
- With a price/sales ratio of 706.32, ARGENX SE has a higher such ratio than 99.29% of stocks in our set.
- Revenue growth over the past 12 months for ARGENX SE comes in at -47.95%, a number that bests just 3.98% of the US stocks we're tracking.
- Stocks with similar financial metrics, market capitalization, and price volatility to ARGENX SE are SWKS, YMAB, API, APLS, and GWH.
- Visit ARGX's SEC page to see the company's official filings. To visit the company's web site, go to www.argenx.com.
ARGX Stock Price Chart Interactive Chart >
ARGX Price/Volume Stats
| Current price | $380.90 | 52-week high | $407.93 |
| Prev. close | $382.10 | 52-week low | $249.50 |
| Day low | $371.85 | Volume | 297,200 |
| Day high | $385.27 | Avg. volume | 234,978 |
| 50-day MA | $382.63 | Dividend yield | N/A |
| 200-day MA | $359.52 | Market Cap | 21.07B |
arGEN-X SE ADR (ARGX) Company Bio
argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancers, today announced its 2021 corporate priorities and highlighted recent achievements from its late-stage immunology pipeline driven by its FcRn antagonist, efgartigimod. Additionally, the Company announced interim data from the Phase 2 CULMINATE trial of cusatuzumab in development with Cilag GmbH International, an affiliate of Janssen, and provided financial guidance for 2021. (Source:Wiki)
Latest ARGX News From Around the Web
Below are the latest news stories about ARGENX SE that investors may wish to consider to help them evaluate ARGX as an investment opportunity.
argenx Announces Extraordinary General Meeting of Shareholders on February 27, 2023 to Appoint Steve Krognes as Non-Executive DirectorJanuary 16, 2023 Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced an extraordinary general meeting of shareholders will be held at 12:00 PM CET on Monday, February 27, 2023 at the Hilton Amsterdam Schiphol at Schiphol Boulevard 701, 1118 BN Schiphol, the Netherlands.The shareholders and all other persons with meeting rights are invited to attend the e |
argenx Highlights 2023 Strategic Priorities Across Immunology PipelineReported $402 million in preliminary* full-year 2022 global net VYVGART sales ADHERE topline results now expected in second quarter of 2023; Stage B enrollment has surpassed projected target of 130 patients Registrational trial of efgartigimod in thyroid eye disease (TED) to start in 2023; additional proof-of-concept trials to start in ANCA-associated vasculitis and antibody mediated rejection (AMR) Submission for marketing approval in Japan of VYVGART for immune thrombocytopenia (ITP) expected |
argenx to Present at 41st Annual J.P. Morgan Healthcare ConferenceJanuary 3, 2023Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Tim Van Hauwermeiren, Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 at 9:00 a.m. PT. A live webcast of the presentation may be accessed on the Investors section of the argenx website at argenx.com/investors. A repla |
argenx Appoints Ana Cespedes to Board of DirectorsDecember 12, 2022 Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced that during the extraordinary general meeting of shareholders held today at 12:00pm CET, Ana Cespedes was appointed as non-executive director to its Board of Directors. Ana Cespedes brings robust experience across a broad range of critical areas for commercialization and access, as well as f |
argenx to Present Pivotal ADVANCE Trial Data During ASH Plenary Session Highlighting VYVGART® (efgartigimod alfa-fcab) as Potential New Treatment Modality for Immune ThrombocytopeniaFirst immune thrombocytopenia (ITP) plenary selection in 15 years underscores significant unmet need in this rare, serious autoimmune bleeding disease VYVGART showed rapid, clinically and statistically significant improvements in platelet counts compared with placebo; safety profile consistent with previous trials Topline data from ADVANCE-SC trial of subcutaneously (SC) administered VYVGART for ITP expected in second half of 2023 Amsterdam, the Netherlands – December 10, 2022 – argenx SE (Euron |
ARGX Price Returns
| 1-mo | 1.36% |
| 3-mo | -2.08% |
| 6-mo | 7.30% |
| 1-year | 47.21% |
| 3-year | 157.03% |
| 5-year | 359.86% |
| YTD | 0.55% |
| 2022 | 8.18% |
| 2021 | 19.08% |
| 2020 | 83.21% |
| 2019 | 67.09% |
| 2018 | 52.15% |
Continue Researching ARGX
Want to do more research on Argenx Se's stock and its price? Try the links below:Argenx Se (ARGX) Stock Price | Nasdaq
Argenx Se (ARGX) Stock Quote, History and News - Yahoo Finance
Argenx Se (ARGX) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...